Xerostomia News and Research

RSS
Xerostomia is the medical term for the subjective complaint of dry mouth due to a lack of saliva. Xerostomia is sometimes colloquially called pasties, cottonmouth, drooth, doughmouth or des (like a desert). Xerostomia is also common in smokers.
Leading dental and pharmacy organizations to raise awareness on xerostomia

Leading dental and pharmacy organizations to raise awareness on xerostomia

Submandibular gland transfer can help prevent dry mouth in cancer patients

Submandibular gland transfer can help prevent dry mouth in cancer patients

MD Anderson receives $2.7 million NCI grant for acupuncture study in cancer

MD Anderson receives $2.7 million NCI grant for acupuncture study in cancer

New lozenge clinical trial for dry mouth treatment

New lozenge clinical trial for dry mouth treatment

Study investigates risk of dysphagia after radiotherapy treatment for head & neck cancer

Study investigates risk of dysphagia after radiotherapy treatment for head & neck cancer

Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Biovex announces OncoVEXGM-CSF Phase 3 study for head and neck cancer

Biovex announces OncoVEXGM-CSF Phase 3 study for head and neck cancer

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Cyclacel reports preclinical data of CYC065 for treatment of cancer, other serious diseases

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Cyclacel announces publication of sapacitabine in British Journal of Cancer

Access highlights clinical benefits of MuGard at ESMO conference

Access highlights clinical benefits of MuGard at ESMO conference

Cyclacel announces completion of private placement sale

Cyclacel announces completion of private placement sale

Mucoadhesive patch increases salivary flow rates for dry mouth sufferers: Study

Mucoadhesive patch increases salivary flow rates for dry mouth sufferers: Study

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Study finds acupuncture can control side effects of cancer treatment

Study finds acupuncture can control side effects of cancer treatment

Cyclacel second-quarter net loss decreases to $6.5 million

Cyclacel second-quarter net loss decreases to $6.5 million

Implantable artificial salivary gland to be developed for Xerostomia patients

Implantable artificial salivary gland to be developed for Xerostomia patients

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS

FDA grants Cyclacel's sapacitabine orphan drug designation for AML and MDS